Want to see FR:CVX full AI Analyst Report?
Top Page
Affluent Medical SA
(CVX)
Select Model
Select Model
Rating:52Neutral
Price Target:
€6.00
▼(-6.25% Downside)
Action:Reiterated
Date:08/26/26
The score is constrained primarily by weak financial performance (zero 2025 revenue, widening losses, persistent cash burn, and higher leverage). Technicals provide a meaningful offset with strong momentum above key moving averages and positive MACD, while valuation remains challenged due to a negative P/E and no dividend yield data.
Positive Factors
Diversified Product Pipeline
The company is pursuing several implantable device candidates across structural heart and urology, reducing reliance on a single product or indication. If development succeeds, this breadth could support multiple commercialization pathways and create a broader platform for future growth.
Negative Factors
No Reported Revenue
Zero reported revenue shows that the company has not yet established a dependable commercial revenue base. This leaves near-term performance highly dependent on successful development and approval of its candidates, while limiting internal funding for continued operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Product Pipeline
The company is pursuing several implantable device candidates across structural heart and urology, reducing reliance on a single product or indication. If development succeeds, this breadth could support multiple commercialization pathways and create a broader platform for future growth.
Read all positive factors
Affluent Medical SA (CVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€368.38M
Dividend YieldN/A
Average Volume (3M)17.61K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-100.00%
EPS Growth-72.33%
CountryFR
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,278,385
10 Day Avg. Volume19,495
30 Day Avg. Volume17,607
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Affluent Medical SA Business Overview & Revenue Model
Company Description
Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavo...
Affluent Medical SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 4.12M | 1.22M | 1.34M | 1.45M |
| Gross Profit | -3.30M | -2.19M | -9.27M | -1.20M | -1.10M | -1.29M |
| EBITDA | -21.00M | -15.81M | -13.43M | -12.95M | -13.32M | -10.98M |
| Net Income | -29.48M | -24.97M | -14.74M | -15.65M | -15.23M | -14.82M |
Balance Sheet | ||||||
| Total Assets | 99.69M | 47.83M | 60.86M | 56.62M | 60.02M | 70.03M |
| Cash, Cash Equivalents and Short-Term Investments | 7.02M | 1.76M | 6.62M | 1.66M | 2.58M | 11.41M |
| Total Debt | 19.48M | 24.04M | 16.33M | 17.13M | 17.73M | 19.75M |
| Total Liabilities | 56.34M | 42.28M | 30.59M | 25.15M | 26.19M | 26.50M |
| Stockholders Equity | 43.35M | 5.55M | 30.27M | 31.47M | 33.83M | 43.53M |
Cash Flow | ||||||
| Free Cash Flow | -18.13M | -11.72M | -11.47M | -12.24M | -11.23M | -12.70M |
| Operating Cash Flow | -17.98M | -11.61M | -11.32M | -12.05M | -11.08M | -12.36M |
| Investing Cash Flow | -4.22M | 5.25M | -480.00K | -184.00K | -146.00K | -160.00K |
| Financing Cash Flow | 17.48M | 6.88M | 11.37M | 11.32M | 2.40M | 18.28M |
Affluent Medical SA Technical Analysis
Positive
6.40
Price Trends
5.83
Positive
5.40
Positive
4.22
Positive
Market Momentum
>-0.01
Negative
57.02
Neutral
88.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CVX, the sentiment is Positive. The current price of 6.4 is above the 20-day moving average (MA) of 5.57, above the 50-day MA of 5.83, and above the 200-day MA of 4.22, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.02 is Neutral, neither overbought nor oversold. The STOCH value of 88.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:CVX.
Affluent Medical SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €368.38M | -9.11 | -120.57% | ― | -100.00% | -72.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | €21.01M | 1.73 | -157.72% | ― | 3.38% | ― | |
45 Neutral | €22.00M | -5.34 | 671.47% | ― | 24.35% | 15.00% | |
43 Neutral | €39.84M | -5.22 | 453.10% | ― | -16.98% | 20.31% | |
41 Neutral | €200.21M | -3.69 | 90.10% | ― | 1.79% | 15.89% |
* Healthcare Sector Average
FR:CVX
Affluent Medical SA
5.94
4.55
325.81%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.11
0.01
12.90%
FR:ALTHE
Theraclion SA
0.59
-0.05
-7.73%
FR:ALDMS
Diagnostic Medical Systems
0.91
-0.44
-32.30%
FR:ALMDT
Median Technologies
4.23
1.02
32.03%
FR:ALIMP
Implanet SA
0.15
-0.12
-43.98%
Affluent Medical SA Corporate Events
Carvolix Updates Share Capital and Voting Rights Structure
Oct 8, 2026
French medtech group Carvolix, which develops AI-guided interventional mini-robots and biomimetic heart valves for structural heart disease and stroke, reported its latest share capital and voting rights structure as of 30 September 2026. The comp...
Carvolix Strengthens Governance and Funding as TAVIPILOT and Kalios Advance Clinically
Sep 30, 2026
Carvolix has appointed technology investor and seasoned board member Anne Lange as chair, reinforcing its governance with new observers and scientific advisors as it pursues global medtech leadership. The leadership shift is designed to accelerate...
Carvolix files FDA submission for TAVIPILOT robot amid expanding U.S. TAVI market
Sep 22, 2026
Carvolix has filed a 510(k) application with the U.S. Food and Drug Administration for its TAVIPILOT robot, the hardware component of its AI-guided platform for transcatheter aortic valve implantation, marking a key step toward a planned U.S. laun...
Carvolix updates share capital and voting rights structure
Sep 11, 2026
Carvolix has disclosed updated figures for its share capital and voting rights as of 31 August 2026, reporting 62,275,177 shares in issue. The company also detailed 90,262,800 theoretical voting rights and 90,220,436 exercisable voting rights, in ...
Carvolix Files for CE Marking to Launch TAVIPILOT AI TAVI Software in Europe
Sep 9, 2026
Carvolix has submitted the regulatory dossier for its TAVIPILOT AI software to obtain EU CE marking, aiming to clear this milestone by year-end 2026 and pave the way for a European commercial launch in early 2027. The company plans a phased rollou...
Carvolix and Truffle Capital Launch Franco-Saudi SAF-MD Program and Plan Saudi MedTech Hub
Aug 24, 2026
Truffle Capital and its portfolio company Carvolix SA, together with Carvolix Saudi LLC, have launched the SAF-MD Saudi–French Medical Exchange and Cooperation Program, coinciding with the visit of Saudi Crown Prince Mohammed bin Salman to F...
Carvolix Secures €30 Million Structured Debt to Fund AI-Driven Cardio Robotics Push
Aug 6, 2026
Carvolix has secured up to €30 million in structured debt financing from Claret Capital Partners, comprising senior secured convertible and amortised bonds plus warrants, with an initial €10 million already drawn and maximum dilution c...
Carvolix Updates Market on Share Capital and Voting Rights Structure
Aug 4, 2026
Carvolix has reported that its share capital as of 31 July 2026 comprises 62,275,177 shares, corresponding to a theoretical total of 90,533,664 voting rights and 90,494,912 exercisable voting rights. The disclosure, made in line with French market...
ODDO BHF Launches Outperformance Coverage on Carvolix, Signaling Strong Upside Potential
Jul 29, 2026
Carvolix has gained fresh attention in the equity markets after ODDO BHF initiated coverage of the stock with an Outperformance recommendation and a price target of €10.5, implying an 89% upside from the prior closing price. The new rating b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.